Table 2.

Univariate analysis of 120 patients with ovarian cancer

Variables	OS		P	PFS		P
	Mean ± SE	5-year (%)		Mean ± SE	5-year (%)
JARID1B expression			<.001			<.001
Low	4.71 ± 0.07	92		4.27 ± 0.09	85
High	3.35 ± 0.24	28		2.37 ± 0.22	17
Residual tumor size			0.01			0.02
<1 cm	4.45 ± 0.24	51		3.45 ± 0.23	41
1–2 cm	3.37 ± 0.38	35		2.30 ± 0.33	25
≥2 cm	1.35 ± 0.29	24		0.60 ± 0.13	22
Serum CA-125 level			0.16			0.28
<35	3.24 ± 0.37	71		2.07 ± 0.17	57
≥35	4.07 ± 0.22	44		3.12 ± 0.21	36
Ascites			0.77			0.96
<100	2.49 ± 0.27	50		2.45 ± 0.37	37.5
≥100	4.15 ± 0.23	45		3.19 ± 0.22	37
Lymph node metastasis			0.02			0.003
Absent	3.67 ± 0.21	54		2.86 ± 0.19	48
Present	3.75 ± 0.33	28		2.53 ± 0.29	14
Histopathological differentiationa			0.12			0.035
G1	3.96 ± 0.34	60		2.09 ± 0.22	52
G2	3.82 ± 0.29	50		3.13 ± 0.25	44
G3	3.72 ± 0.32	35		2.65 ± 0.28	26
Histology type			0.12			0.36
Serous adenocarcinoma	4.35 ± 0.24	48		3.34 ± 0.23	39
Mucoid adenocarcinoma	3.90 ± 0.49	50		2.01 ± 0.31	41
Endometrioid adenocarcinoma	2.11 ± 0.35	31		1.41 ± 0.22	26
Clear cell carcinoma	2.02	100		1.66	100
Age (years)			0.93			0.91
<50	3.75 ± 0.25	42		2.64 ± 0.23	34
≥50	4.08 ± 0.28	47		3.19 ± 0.26	39
Chemotherapy regimen			<.001			<.001
TP	5.33 ± 0.26	73		4.29 ± 0.26	61
PAC	2.76 ± 0.20	21		2.08 ± 0.21	16
FIGO stage			0.02			0.004
I and II	4.21478 ± 0.21885	47.46		3.25888 ± 0.20959	38.73
III and IV	2.28819 ± 0.63153	–		1.08681 ± 0.31846	–

OS overall survival time. PFS progression-free survival time, TP cisplatin and paclitaxel, PAC cisplatin, epirubicin, and cyclophosphamide

^aG1 is well differentiated, G2 moderately differentiated, and G3 poorly differentiated